modelDipyrocetylAndCorticoste

Diagram of DipyrocetylAndCorticoste

Extends from Pharmacolibrary.Drugs.ATC.M.M01BA02.

Information

name:DipyrocetylAndCorticosteroids
ATC code:M01BA02
route:oral
compartments:1
dosage:500mg
volume of distribution:15L
clearance:1000mL/min
other parameters in model implementation

Dipyrocetyl is an obscure or possibly obsolete analgesic/antipyretic compound; 'dipyrocetyl and corticosteroids' is a fixed-dose combination drug classified under ATC code M01BA02, indicated historically for inflammatory, rheumatic, and pain-related conditions. It is not widely approved or used in current clinical practice, and available data on its clinical use is extremely limited.

Pharmacokinetics

No published pharmacokinetic data found in literature or scientific databases for dipyrocetyl, or its combination with corticosteroids, for any population. The below parameters were estimated based on pharmacokinetic properties typical of non-steroidal anti-inflammatory drugs (such as salicylic acid derivatives) for reference adult individuals.

References

  1. Krzyzanski, W, et al., & Jusko, WJ (2021). Population pharmacokinetic modeling of intramuscular and oral dexamethasone and betamethasone in Indian women. Journal of pharmacokinetics and pharmacodynamics 48(2) 261–272. DOI:10.1007/s10928-020-09730-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/33389521

  2. Hamitouche, N, et al., & Laviolle, B (2017). Population Pharmacokinetic-Pharmacodynamic Model of Oral Fludrocortisone and Intravenous Hydrocortisone in Healthy Volunteers. The AAPS journal 19(3) 727–735. DOI:10.1208/s12248-016-0041-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28083797

  3. Werumeus Buning, J, et al., & van Beek, AP (2017). Pharmacokinetics of oral hydrocortisone - Results and implications from a randomized controlled trial. Metabolism: clinical and experimental 71 7–16. DOI:10.1016/j.metabol.2017.02.005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28521880

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)